Primary Skull Base Chordomas: A Clinicopathological Analysis of 94 Patients

World Neurosurg. 2023 Jul:175:e841-e854. doi: 10.1016/j.wneu.2023.04.032. Epub 2023 Apr 15.

Abstract

Objective: To investigate prognostic factors in patients with primary skull base chordoma (PSBC) to guide future therapeutic advances.

Methods: This retrospective cohort study of 94 PSBC patients was conducted in 2 institutions from January 2006 to December 2013. Independent predictors for progression-free survival (PFS) and overall survival were established with multivariate Cox regression analysis.

Results: Age (P = 0.006), extent of resection (P = 0.037), and radiotherapy (RT) (P = 0.027) were established as independent predictors for PFS in PSBC patients. Similarly, age (P = 0.002), extent of resection (P = 0.048), and RT (P = 0.015) were established as independent predictors for overall survival. Meta-analysis manifested that lower MIB-1 correlated with longer PFS in skull base chordoma patients (P < 0.001). RT doubled the 5-year PFS rate from 28.6 ± 12.1% to 61.6 ± 10.7% (P = 0.031) and increased the 5-year overall survival rate from 54.5 ± 13.8% to 84.2 ± 8.4% (P = 0.020) in the subtotal resection/partial resection and MIB-1 labeling index (STR/PR+MIB-1 LI) <2% subgroup. In contrast, in the STR/PR+MIB-1 LI ≥2% subgroup, the survival benefit of RT remained uncertain. Further analysis revealed no survival difference between different RT modalities in STR/PR PSBC patients.

Conclusions: In PSBC patients, age, extent of resection, and adjuvant RT all are independent predictors for PFS. Lower MIB-1 LI is associated with longer PFS in PSBC patients. Adjuvant RT is necessary for PSBC patients who undergo STR/PR with MIB-1 LI <2%. Patients who undergo GTR or STR/PR with MIB-1 LI ≥2% seem nonresponsive to RT.

Keywords: Gross total resection; MIB-1 labeling index; Primary skull base chordoma; Progression-free survival; Radiotherapy.

Publication types

  • Meta-Analysis

MeSH terms

  • Chordoma* / radiotherapy
  • Chordoma* / surgery
  • Humans
  • Progression-Free Survival
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Skull Base / pathology
  • Skull Base Neoplasms* / radiotherapy
  • Skull Base Neoplasms* / surgery
  • Treatment Outcome